Please login to the form below

Not currently logged in
Email:
Password:

Opsumit

This page shows the latest Opsumit news and features for those working in and with pharma, biotech and healthcare.

FDA ‘names and shames’ generic-blocking pharma companies

FDA ‘names and shames’ generic-blocking pharma companies

Pomalyst, followed by Actelion with 26 inquiries mainly for pulmonary artery hypertension drugs Tracleer and Opsumit.

Latest news

More from news
Approximately 7 fully matching, plus 10 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag). ... He also led and managed the highly successful launches of Opsumit,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....